S1PR1 and myeloid sarcoma: Fingolimod is effective on MS by preventing the recruitment of T cells, expressing S1P1 and S1P3 receptors, with their consequent redistribution to secondary lymphoid organs, and preventing invasion of auto-aggressive T cells to the CNS.